{"id":"123i-meta-iodobenzylguanidine","safety":{"commonSideEffects":[{"rate":null,"effect":"Radiation exposure"},{"rate":null,"effect":"Allergic reaction to iodine"},{"rate":null,"effect":"Thyroid uptake of free iodide"}]},"_chembl":{"chemblId":"CHEMBL1615777","moleculeType":"Small molecule","molecularWeight":"271.09"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This radiopharmaceutical is an iodine-123 labeled analog of guanethidine that mimics norepinephrine and is taken up by the norepinephrine transporter (NET) in neuroendocrine cells and sympathetic nerve terminals. Once accumulated in target tissues, the radioactive iodine-123 emits gamma radiation that can be detected by gamma cameras to create diagnostic images. It is used primarily for imaging neuroendocrine tumors such as pheochromocytoma, paraganglioma, and carcinoid tumors.","oneSentence":"123I-meta-iodobenzylguanidine is a radiolabeled imaging agent that accumulates in neuroendocrine tumors and the sympathetic nervous system, allowing visualization via nuclear scintigraphy.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:41:43.100Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Imaging of neuroendocrine tumors including pheochromocytoma and paraganglioma"},{"name":"Imaging of carcinoid tumors"},{"name":"Assessment of sympathetic nervous system function"}]},"trialDetails":[{"nctId":"NCT06858501","phase":"PHASE2","title":"Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma","status":"NOT_YET_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2026-06-22","conditions":"Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, High Risk Neuroblastoma","enrollment":84},{"nctId":"NCT03126916","phase":"PHASE3","title":"Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2018-05-14","conditions":"Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":750},{"nctId":"NCT04385277","phase":"PHASE2","title":"Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2020-12-31","conditions":"Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":41},{"nctId":"NCT07064746","phase":"","title":"Clinical Application Study of [123I]Metaiodobenzylguanidine and Somatostatin Receptor-Targeted Imaging in the Diagnosis and Staging of Neuroblastoma","status":"RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2022-07-10","conditions":"Neuroblastoma (NB)","enrollment":150},{"nctId":"NCT05514106","phase":"PHASE4","title":"MIBG in Aging and Neurologic Disorders","status":"ENROLLING_BY_INVITATION","sponsor":"Mayo Clinic","startDate":"2023-05-08","conditions":"Lewy Body Disease, Dementia, Parkinsonism","enrollment":50},{"nctId":"NCT04510311","phase":"EARLY_PHASE1","title":"Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2020-10-19","conditions":"Neuroendocrine Tumors","enrollment":32},{"nctId":"NCT03217227","phase":"","title":"Evaluating Myocardial Ischemia in Chest Pain Using Exercise CMR","status":"UNKNOWN","sponsor":"National Heart Centre Singapore","startDate":"2017-05-01","conditions":"Ischemic Heart Disease, Coronary Artery Disease, Cardiovascular Diseases","enrollment":300},{"nctId":"NCT01912040","phase":"","title":"Study Of the Safety of Locally Manufactured 123I-metaiodobenzylguanidine(MIBG) in Routine Clinical Use","status":"WITHDRAWN","sponsor":"Nova Scotia Health Authority","startDate":"2006-07","conditions":"Adrenergic Pathology","enrollment":""},{"nctId":"NCT03469843","phase":"","title":"Characterization of the Cardiac Reinnervation of Patients With Transposition of the Great Arteries Long After Repair With the Arterial Switch Operation. Correlation With Electrocardiographic and Exercise Test Parameters","status":"COMPLETED","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2018-04-19","conditions":"Congenital Heart Disease, Congenital Heart Defect, Transposition of the Great Arteries","enrollment":25},{"nctId":"NCT02279030","phase":"","title":"Use of MIBG Scan Images in PVC Ablations","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2015-06","conditions":"Premature Ventricular Contractions","enrollment":20},{"nctId":"NCT01250912","phase":"NA","title":"Imaging With a Radio Tracer to Guide VT Ablations","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2010-03","conditions":"Ventricular Tachycardia, Arrhythmia","enrollment":20},{"nctId":"NCT02043899","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of [124I]mIBG PET/CT in Neuroblastoma","status":"COMPLETED","sponsor":"Cancer Research UK","startDate":"2014-02","conditions":"Metastatic Neuroblastoma","enrollment":36},{"nctId":"NCT01940081","phase":"","title":"The Leiden Nonischemic Cardiomyopathy Study","status":"COMPLETED","sponsor":"Leiden University Medical Center","startDate":"2011-10","conditions":"Cardiomyopathy, Dilated, Tachycardia, Ventricular, Ventricular Fibrillation","enrollment":148},{"nctId":"NCT00126412","phase":"PHASE3","title":"Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma","status":"COMPLETED","sponsor":"GE Healthcare","startDate":"2005-08-02","conditions":"Pheochromocytoma, Neuroblastoma","enrollment":251},{"nctId":"NCT02656329","phase":"PHASE3","title":"International Study to Determine if AdreView Heart Function Scan Can be Used to Identify Patients With Mild or Moderate Heart Failure (HF) That Benefit From Implanted Medical Device","status":"TERMINATED","sponsor":"GE Healthcare","startDate":"2015-12-30","conditions":"Heart Failure","enrollment":395},{"nctId":"NCT00126438","phase":"PHASE3","title":"Meta-Iodobenzylguanidine (123I-mIBG) Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease","status":"COMPLETED","sponsor":"GE Healthcare","startDate":"2005-07","conditions":"Heart Failure, Congestive","enrollment":515},{"nctId":"NCT01185756","phase":"NA","title":"MIBG Scintigraphy as a Tool for Selecting Patients Requiring Implantable Cardioverter Defibrillator (ICD)","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2010-09","conditions":"Heart Failure, Sudden Death","enrollment":330},{"nctId":"NCT00028106","phase":"PHASE2","title":"131MIBG to Treat Malignant Pheochromocytoma","status":"COMPLETED","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"2001-12-05","conditions":"Pheochromocytoma","enrollment":32},{"nctId":"NCT01522378","phase":"PHASE1","title":"Cardiac Resynchronization and Iodine Meta-Iodobenzylguanidine (MIBG) Imaging","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2012-02","conditions":"Congestive Heart Failure","enrollment":14},{"nctId":"NCT02043522","phase":"PHASE3","title":"123I-mIBG SPECT Imaging","status":"COMPLETED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2013-12","conditions":"Heart Failure, Coronary Artery Disease","enrollment":30},{"nctId":"NCT01258283","phase":"","title":"PET / CT With 18F-FDG: Does it Optimize the I 123-MIBG Imaging Results in the Search for Discriminating Factors for the Implementation of an Implantable Defibrillator?","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2011-06","conditions":"Defibrillators, Implantable","enrollment":6},{"nctId":"NCT02071680","phase":"PHASE3","title":"Autonomic Innervation and MIBG Imaging","status":"COMPLETED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2015-03","conditions":"Atrial Fibrillation","enrollment":5},{"nctId":"NCT00126425","phase":"PHASE3","title":"Meta-Iodobenzylguanidine Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease","status":"COMPLETED","sponsor":"GE Healthcare","startDate":"2005-07","conditions":"Heart Failure, Congestive","enrollment":587},{"nctId":"NCT01936649","phase":"PHASE4","title":"Open-label, Test-retest Study Assessing Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView.","status":"COMPLETED","sponsor":"GE Healthcare","startDate":"2013-08","conditions":"Heart Failure (HF), Ventricular Dysfunction, Left","enrollment":63},{"nctId":"NCT01432626","phase":"NA","title":"Pathogenesis of Stress-Induced Cardiomyopathy by I-123 MIBG","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2011-09","conditions":"Stress Induced Cardiomyopathy","enrollment":10},{"nctId":"NCT02173834","phase":"NA","title":"Brown Adipose Tissue and Body Mass Index","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2013-03","conditions":"Obesity, Type 2 Diabetes Mellitus","enrollment":20},{"nctId":"NCT01730417","phase":"PHASE1","title":"Phase I Study of the Safety, Distribution, and Radiation Dosimetry of Ultratrace Iobenguane 123I-mIBG","status":"COMPLETED","sponsor":"Bennett Chin","startDate":"2009-11","conditions":"Neuroendocrine Tumors, Heart Failure","enrollment":12},{"nctId":"NCT01373736","phase":"PHASE3","title":"123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors","status":"UNKNOWN","sponsor":"Vancouver Coastal Health","startDate":"","conditions":"Pheochromocytoma, Neuroblastoma, Paraganglioma","enrollment":""},{"nctId":"NCT00730444","phase":"","title":"Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma","status":"APPROVED_FOR_MARKETING","sponsor":"GE Healthcare","startDate":"","conditions":"Neuroblastoma","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":75,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"123I-meta-iodobenzylguanidine","genericName":"123I-meta-iodobenzylguanidine","companyName":"Vancouver Coastal Health","companyId":"vancouver-coastal-health","modality":"Small molecule","firstApprovalDate":"","aiSummary":"123I-meta-iodobenzylguanidine is a radiolabeled imaging agent that accumulates in neuroendocrine tumors and the sympathetic nervous system, allowing visualization via nuclear scintigraphy. Used for Imaging of neuroendocrine tumors including pheochromocytoma and paraganglioma, Imaging of carcinoid tumors, Assessment of sympathetic nervous system function.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}